The German medtech company Viromed Medical is charting an aggressive growth trajectory, with management targeting roughly €80 million in revenue for the 2026 financial year — a near tenfold leap from the single-digit millions expected in the current period. The ambitious forecast hinges on the successful market rollout of two key product families: the wound-healing ViroCAP system and the pulmonary-focused PulmoPlas platform.
From Distributor to Vertically Integrated Player
A pivotal shift in the company’s business model is underway. Viromed plans to fully absorb relyon plasma GmbH in the second quarter, transforming itself from a pure distribution specialist into a vertically integrated technology operation. The acquisition brings in-house research and manufacturing capabilities for atmospheric cold plasma technology, cutting the company’s reliance on external production partners.
“We are building a proprietary technology platform that spans from R&D to serial production,” the company has indicated, pointing to an already operational manufacturing run for the Hellmut Ruck GmbH podology sector as early proof of concept.
The Science Behind the Strategy
Cold plasma technology works by physically destroying pathogens without relying on antibiotics — a mechanism that has drawn increasing attention as antimicrobial resistance spreads across intensive care units worldwide. Viromed is developing the PulmoPlas system in collaboration with Hannover Medical School and the Helmholtz Centre for Infection Research, with early data suggesting it could complement or even replace conventional therapies for severe respiratory infections.
While ViroCAP is already moving toward operational deployment for wound care, PulmoPlas still faces the regulatory gauntlet. The goal is to make the system available in select hospitals for severe cases, with clinical certification serving as the next major catalyst for the stock.
Should investors sell immediately? Or is it worth buying VIROMED MEDICAL?
Patent Portfolio and International Ambitions
The company has been building a broad international patent estate to protect its cold plasma intellectual property. Management plans to unveil details on global distribution strategy and partnerships in the Middle East in the coming months. Expansion into Asian markets is also on the agenda, though the company acknowledges that sales channel development there must proceed smoothly for the revenue targets to materialize.
Viromed is currently showcasing its technology at the EWMA wound healing conference in Bremen, targeting an international specialist audience.
Stock Volatility Reflects High Stakes
Shares in Viromed have rallied roughly 36% over the past month, trading around €7.20, though the stock remains highly volatile with an annualized 30-day figure of nearly 76%. The relative strength index sits at 35.5, suggesting a short-term oversold condition despite the recent gains.
With a market capitalization of approximately €144 million, the stock already prices in considerable expectations. The company’s annual general meeting in July is seen as a key event, where management will need to outline how it intends to finance the ambitious expansion — concrete details on capital structure remain outstanding.
The operating profit margin target for 2026 is in the clearly double-digit range, but the path to profitability runs squarely through regulatory approvals for the human-use medical devices. If PulmoPlas secures clinical certification and gains entry to initial hospitals, the scientific validation could translate into a tangible milestone — turning the cold plasma vision into a commercial reality.
Ad
VIROMED MEDICAL Stock: Buy or Sell?! New VIROMED MEDICAL Analysis from May 6 delivers the answer:
The latest VIROMED MEDICAL figures speak for themselves: Urgent action needed for VIROMED MEDICAL investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 6.
VIROMED MEDICAL: Buy or sell? Read more here...
